Analysts Set Replimune Group, Inc. (NASDAQ:REPL) Price Target at $16.80

Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) has earned a consensus rating of "Buy" from the six analysts that are covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $16.80.

REPL has been the topic of a number of recent analyst reports. Roth Mkm assumed coverage on Replimune Group in a report on Tuesday, August 27th. They set a "buy" rating and a $17.00 price target on the stock. Roth Capital upgraded shares of Replimune Group to a "strong-buy" rating in a research report on Tuesday, August 27th. JPMorgan Chase & Co. upped their price target on shares of Replimune Group from $14.00 to $17.00 and gave the company an "overweight" rating in a research note on Tuesday, September 24th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Replimune Group in a report on Tuesday.

Insider Transactions at Replimune Group

In other news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the transaction, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.80% of the stock is currently owned by insiders.

Institutional Trading of Replimune Group

A number of institutional investors have recently made changes to their positions in REPL. Acadian Asset Management LLC purchased a new position in Replimune Group during the 1st quarter valued at about $927,000. Jacobs Levy Equity Management Inc. purchased a new position in shares of Replimune Group in the 1st quarter valued at approximately $1,088,000. Price T Rowe Associates Inc. MD lifted its position in Replimune Group by 12.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company's stock valued at $53,505,000 after buying an additional 699,679 shares during the period. Millennium Management LLC grew its position in shares of Replimune Group by 575.1% in the 2nd quarter. Millennium Management LLC now owns 3,118,035 shares of the company's stock worth $28,062,000 after buying an additional 2,656,173 shares during the period. Finally, Cubist Systematic Strategies LLC increased its stake in shares of Replimune Group by 282.2% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company's stock worth $650,000 after acquiring an additional 53,313 shares in the last quarter. Hedge funds and other institutional investors own 92.53% of the company's stock.

Replimune Group Stock Down 2.5 %

REPL stock traded down $0.31 during midday trading on Tuesday, reaching $12.19. 460,407 shares of the company's stock traded hands, compared to its average volume of 1,040,354. The company has a market cap of $832.82 million, a price-to-earnings ratio of -3.75 and a beta of 1.19. Replimune Group has a 52 week low of $4.92 and a 52 week high of $12.97. The firm's fifty day moving average price is $11.33 and its 200-day moving average price is $9.40. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.